Variations in Radioiodine Ablation: Decision-making After Total Thyroidectomy

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2019 Nov 11

PMID 31707428

Citations 5

Authors

O Maas

F Forrer

M Maas

C M Panje

J Blautzik

M Bruhlmeier

I Engel-Bicik

L Giovanella

A Haldemann

M E Kamel

S Kneifel

C Rottenburger

N Schaefer

M A Walter

S Weidner

P M Putora

Affiliations

Soon will be listed here.

Abstract

Background: The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.

Methods: We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.

Citing Articles

Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative I Administration: A Real Life Study.

Campenni A, Ruggeri R, Garo M, Siracusa M, Restuccia G, Rappazzo A Cancers (Basel). 2023; 15(9).

PMID: 37173884 PMC: 10177573. DOI: 10.3390/cancers15092416.

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.

Gao H, Huang J, Dai Q, Su J Arch Endocrinol Metab. 2023; 67(2):197-205.

PMID: 36651706 PMC: 10689029. DOI: 10.20945/2359-3997000000538.

Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Forrer F, Fischer G, Maas O, Giovanella L, Hoffmann M, Iakovou I Oncology. 2021; 100(2):74-81.

PMID: 34788758 PMC: 8985029. DOI: 10.1159/000520938.

Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database.

Schwengber W, Mota L, Nava C, Rodrigues J, Zanella A, de Souza Kuchenbecker R Arch Endocrinol Metab. 2020; 64(6):824-832.

PMID: 33085995 PMC: 10528611. DOI: 10.20945/2359-3997000000302.

Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.

Campenni A, Barbaro D, Guzzo M, Capoccetti F, Giovanella L Endocrine. 2020; 70(2):280-291.

PMID: 32772339 PMC: 7581611. DOI: 10.1007/s12020-020-02418-x.

References

Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S . Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. Oncologist. 2015; 20(9):1028-35. PMC: 4571803. DOI: 10.1634/theoncologist.2015-0145. View

Tuttle R . Controversial Issues in Thyroid Cancer Management. J Nucl Med. 2018; 59(8):1187-1194. PMC: 6071505. DOI: 10.2967/jnumed.117.192559. View

Nikiforov Y, Seethala R, Tallini G, Baloch Z, Basolo F, Thompson L . Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016; 2(8):1023-9. PMC: 5539411. DOI: 10.1001/jamaoncol.2016.0386. View

Steffen T, Putora P, Hubner M, Gloor B, Lehmann K, Kettelhack C . Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey. Clin Colorectal Cancer. 2019; 18(4):e335-e342. DOI: 10.1016/j.clcc.2019.06.002. View

Zulewski H, Giovanella L, Bilz S, Christ E, Haldemann A, Steinert H . Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. Swiss Med Wkly. 2019; 149:w14700. DOI: 10.4414/smw.2019.14700. View

Zumstein V, Betschart P, Abt D, Schmid H, Panje C, Putora P . Surgical management of urolithiasis - a systematic analysis of available guidelines. BMC Urol. 2018; 18(1):25. PMC: 5894235. DOI: 10.1186/s12894-018-0332-9. View

Panje C, Glatzer M, von Rappard J, Rothermundt C, Hundsberger T, Zumstein V . Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol. 2017; 17(1):123. PMC: 5559810. DOI: 10.1186/s12874-017-0400-y. View

Hundsberger T, Schoser B, Leupold D, Rosler K, Putora P . Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale. J Neurol. 2019; 266(8):2010-2017. DOI: 10.1007/s00415-019-09373-2. View

Sawka A, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein H . Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004; 89(8):3668-76. DOI: 10.1210/jc.2003-031167. View

10.

Verburg F, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M . Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016; 43(6):1001-5. DOI: 10.1007/s00259-016-3327-3. View

11.

Hay I . Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006; 94(8):692-700. DOI: 10.1002/jso.20696. View

12.

Tuttle R, Ahuja S, Avram A, Bernet V, Bourguet P, Daniels G . Controversies, Consensus, and Collaboration in the Use of I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and.... Thyroid. 2019; 29(4):461-470. DOI: 10.1089/thy.2018.0597. View

13.

Hundsberger T, Hottinger A, Roelcke U, Roth P, Migliorini D, Dietrich P . Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol. 2015; 126(1):175-183. DOI: 10.1007/s11060-015-1957-0. View

14.

Vuong H, Altibi A, Duong U, Hassell L . Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf). 2017; 87(5):411-417. DOI: 10.1111/cen.13413. View

15.

Sacks W, Fung C, Chang J, Waxman A, Braunstein G . The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010; 20(11):1235-45. DOI: 10.1089/thy.2009.0455. View

16.

Putora P, Panje C, Papachristofilou A, Dal Pra A, Hundsberger T, Plasswilm L . Objective consensus from decision trees. Radiat Oncol. 2014; 9:270. PMC: 4269842. DOI: 10.1186/s13014-014-0270-y. View

17.

Hay I, Hutchinson M, Gonzalez-Losada T, McIver B, Reinalda M, Grant C . Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008; 144(6):980-7. DOI: 10.1016/j.surg.2008.08.035. View

18.

Dietlein M, Eschner W, Grunwald F, Lassmann M, Verburg F, Luster M . [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]. Nuklearmedizin. 2016; 55(3):77-89. View

19.

Haugen B . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2016; 123(3):372-381. DOI: 10.1002/cncr.30360. View

20.

Davies L, Welch H . Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295(18):2164-7. DOI: 10.1001/jama.295.18.2164. View